Viking Therapeutics/$VKTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Ticker

$VKTX
Primary listing

Industry

Biotechnology

Employees

49

VKTX Metrics

BasicAdvanced
$3.7B
-
-$1.54
0.62
-

What the Analysts think about VKTX

Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.

Bulls say / Bears say

Viking Therapeutics' VK2735 achieved a 14.7% reduction in body weight during its Phase 2 VENTURE study, surpassing expectations and indicating strong potential in the weight-loss market. (InvestorPlace)
The company has entered a multi-year strategic partnership with CordenPharma to ensure large-scale manufacturing capabilities for VK2735, supporting potential multi-billion-dollar annual product sales. (StockTitan)
Viking Therapeutics plans to advance VK2735 directly to Phase 3 trials, potentially accelerating its market entry by a year and positioning it as a strong competitor in the GLP-1 market. (Yahoo Finance)
Insider selling activity, including CEO Brian Lian's sale of 194,490 shares, may raise concerns about executives' confidence in the company's future prospects. (American Banking and Market News)
Viking Therapeutics faces intense competition from established players like Eli Lilly and Novo Nordisk in the GLP-1 market, which could challenge its market penetration and profitability. (Yahoo Finance)
The company's stock experienced a significant pullback after a nearly 300% increase in the prior quarter, indicating potential volatility and investor uncertainty. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

VKTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VKTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VKTX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs